RxDoctor Payments Data

Shawn Zimberg, MD

Radiation Oncology · Plainview, NYNPI 1528021714

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (46.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Bioprotect Medical, Inc. accounts for 67.0% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $273,594, more than ten times the $24,645 reported in 2019. Among radiation oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$410,823in general payments, 2019–2025

Across 229 payments — averaging $1793.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bioprotect Medical, Inc.$275K
  • Bayer$80K
  • Novartis$22K
  • Bioprotect LTD.$14K
  • Elekta, Inc.$11K
  • Bayer Healthcare LLC$4K
  • plus $4K from 21 others
$65,520in research payments, 2019–2025

Across 5 payments — averaging $13,104 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bioprotect Medical, Inc.$29K
  • Bayer$20K
  • Bioprotect LTD.$16K
$100,000in ownership & investment interests, 2019–2025

Across 2 payments — averaging $50,000 each. An ownership or investment interest held by the physician or an immediate family member.

  • Bioprotect LTD.$100K

What the payments were for

  • Consulting fees$143,63135%
  • Speaking & faculty fees$190,26246%
  • Travel & lodging$69,29217%
  • Food & beverage$7,6392%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$410,823 in reported general payments places this provider in the 95th percentile of 397 radiation oncology providers in New York.

See all radiation oncology providers in New York

Medicare billing

Part B allowed, 2024
$2,686,043
Medicare patients
645
Services billed
9,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl19$134
Methylprednisolone12$72
Diazepam14$31

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Plainview

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →